Become familiarised with pharmacodynamic drug interactions, get comprehensively informed about in vitro and vivo aspects of the ICH M12 drug interaction guidelines, build up knowledge on biomarkets for detecting clinical DDIs and hear the latest update on FDA scientific efforts.

Dr Jorg Taubel, CEO ofRichmond Pharmacology will be attending.

Latest news

How Richmond Pharmacology Ensures End‑to‑End Data Integrity and Operational Continuity

March 13, 2026
Richmond Pharmacology applies a comprehensive, four‑pillar data‑security framework designed to protect participant information...
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event